[Treatment outcome of myelodysplastic syndrome patients younger than 60 years old].
We evaluated the clinical outcome of 92 patients younger than 60 years who were treated between January 1987 and May 2003. Low, Int-1, Int-2 and High risk groups categorized by IPSS consisted of 7, 34, 24 and 27 patients, respectively. There was no significant difference in the overall survival between 30 patients who received allogeneic stem cell transplantation and 62 patients who did not. Allogeneic stem cell transplantation provided significantly better outcomes in the Int-2 and the High risk groups. Risk factors for overall survival were age and disease status at transplantation. Acute and chronic GVHD did not influence the relapse free survival rate. Allogeneic stem cell transplantation is a curative therapy for MDS. It is necessary to reduce transplantation related death and to perform stem cell transplantation as soon as possible for patients with Int-2 or High risk of IPSS.
Matsushima
Takafumi
T
Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine.
Handa
Hiroshi
H
Yokohama
Akihiko
A
Sakura
Tohru
T
Okamoto
Kiyoshi
K
Kawamura
Toshihide
T
Tsumita
Yuki
Y
Murayama
Kayoko
K
Isoda
Atsushi
A
Jinbo
Takahiro
T
Hirabyashi
Hisami
H
Sawamura
Morio
M
Karasawa
Masamitsu
M
Shimano
Shun-ichi
S
Tsukamoto
Norifumi
N
Miyawaki
Shuichi
S
Nojima
Yoshihisa
Y
Murakami
Hirokazu
H
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D016896:Treatment Outcome